Advertisement

 

 

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
Author Information (click to view)

Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K,


Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K, (click to view)

Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Circulation 2017 07 07() pii CIRCULATIONAHA.117.027067
Abstract

Background -Statins are effective in primary prevention of atherosclerotic cardiovascular disease. The 2013 American College of Cardiology/American Heart Association (ACC-AHA) guideline expands recommended statin use, but its cost-effectiveness has not been compared with other guidelines. Methods -We used the Cardiovascular Disease (CVD) Policy Model to estimate the cost-effectiveness of the ACC-AHA, relative to current use, Adult Treatment Panel III (ATP III) guidelines, and universal statin use in all men age 45-74 years and women age 55-74 years over a 10-year horizon from 2016 to 2025. Sensitivity analyses varied costs, risks, and benefits. Main outcomes were incremental cost-effectiveness ratios (ICER) and numbers needed to treat for ten years per quality-adjusted life-year gained (NNT/QALY). Results -Each approach produces substantial benefits and net cost savings relative to the status quo. Full adherence to the ATP III guideline would result in 8.8 million more statin users than the status quo, at an NNT/QALY of 35. The ACC-AHA guideline would potentially result in up to 12.3 million more statin users than the ATP III guideline, with a marginal NNT/QALY of 68. Moderate-intensity statin use in all men 45-74 and women 55-74 would result in 28.9 million more statin users than the ACC-AHA guideline, with a marginal NNT/QALY of 108. In all cases, benefits would be greater in men than women. Results vary moderately with different risk thresholds for instituting statins and statin toxicity estimates, but greatly depend on the disutility caused by daily medication use (pill burden). Conclusions -At a population level, the ACC-AHA guideline for expanded statin use for primary prevention is projected to treat more people, save more lives, and cost less compared with ATP III, in both men and women. Whether individuals benefit from long-term statin use for primary prevention depends more on the disutility associated with pill burden than their degree of cardiovascular risk.

Submit a Comment

Your email address will not be published. Required fields are marked *

ten + seven =

[ HIDE/SHOW ]